Could PD-L1/2 Structural Variants be the Next Pan-Cancer Predictive Immunotherapy Biomarker?

Retrieved on: 2023-01-10 23:09:10

Tags for this article:

Click the tags to see associated articles and topics

Could PD-L1/2 Structural Variants be the Next Pan-Cancer Predictive Immunotherapy Biomarker?. View article details on hiswai:

Excerpt

The identification of PD-L2 structural variants and their biological impact was of particular interest to Roychowdhury's team in this study ...

Article found on: www.precisiononcologynews.com